High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment

Arthritis and Rheumatism

Volumn 46, Issue 7, 2002, Pages 1744-1753

  Ziolkowska, Maria ^a   Kurowska, Mariola ^a   Radzikowska, Anna ^a   Luszczykiewicz, Grazyna ^a   Wiland, Piotr ^b   Dziewczopolski, Wojciech ^a   Filipowicz Sosnowska, Anna ^a   Pazdur, Jacek ^a   Szechinski, Jacek ^b   Kowalczewski, Jacek ^a   Rell Bakalarska, Maria ^a   Maslinski, Wlodzimierz ^c  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INFLIXIMAB; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGE; AGED; ARTICLE; BLOOD ANALYSIS; CELL CULTURE; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VITRO STUDY; INFLAMMATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RHEUMATOID ARTHRITIS; SUPERNATANT; SYNOVIAL FLUID; SYNOVIOCYTE; SYNOVIUM; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM PROTEINS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 0036069790     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10388     Document Type: Article

References (32)

1. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis
2. The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis
3. Osteoprotegerin ligand: A regulator of immune response and bone physiology
4. TRAIL a newly described effector mechanism of cytotoxic lymphocytes
5. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
6. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: Modulation of the expression by osteotropic factors and cytokines
7. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
8. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
9. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40
10. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
11. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
12. The effect of a single dose of osteoprotegerin in postmenopausal women
13. 3
14. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression
15. Role of cytokines in rheumatoid arthritis
16. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism
17. Anti-tumor necrosis factor-a therapy of rheumatoid arthritis
18. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis
19. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis
20. Infliximab and methotrexate in the treatment of rheumatoid arthritis
21. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
22. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
23. Infliximab: A review of its use in the management of rheumatoid arthritis
24. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials
25. Taurine chloramine inhibition of cell proliferation and cytokine production by rheumatoid arthritis fibroblast-like synoviocytes
26. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis
27. Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status
28. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation
29. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis
30. Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients
31. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
32. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor